Product Name :
DKM 2-93
Description:
DKM 2-93 is a relatively selective inhibitor of UBA5 with an IC50 of 430 μM.
CAS:
65836-72-8
Molecular Weight:
243.69
Formula:
C11H14ClNO3
Chemical Name:
2-chloro-N-[(3,4-dimethoxyphenyl)methyl]acetamide
Smiles :
COC1=CC=C(CNC(=O)CCl)C=C1OC
InChiKey:
CETPWRGZGWGPSV-UHFFFAOYSA-N
InChi :
InChI=1S/C11H14ClNO3/c1-15-9-4-3-8(5-10(9)16-2)7-13-11(14)6-12/h3-5H,6-7H2,1-2H3,(H,13,14)
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
DKM 2-93 is a relatively selective inhibitor of UBA5 with an IC50 of 430 μM.Plerixafor site |Product information|CAS Number: 65836-72-8|Molecular Weight: 243.RITA Purity 69|Formula: C11H14ClNO3|Chemical Name: 2-chloro-N-[(3,4-dimethoxyphenyl)methyl]acetamide|Smiles: COC1=CC=C(CNC(=O)CCl)C=C1OC|InChiKey: CETPWRGZGWGPSV-UHFFFAOYSA-N|InChi: InChI=1S/C11H14ClNO3/c1-15-9-4-3-8(5-10(9)16-2)7-13-11(14)6-12/h3-5H,6-7H2,1-2H3,(H,13,14)|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 125 mg/mL (512.PMID:32491746 95 mM; Need ultrasonic).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|Ubiquitin-like modifier activating enzyme 5 (UBA5) is a novel pancreatic cancer therapeutic target. DKM 2-93 impairs pancreatic cancer cell survival through covalently modifying the catalytic cysteine of UBA5, thereby inhibiting its activity as a protein that activates the ubiquitin-like protein UFM1 to UFMylate proteins. DKM 2-93 inhibits PaCa2 and Panc1 cells survival with IC50s of 90 and 30 μM, respectively.|In Vivo:|DKM 2-93 daily treatment significantly impairs tumor growth of PaCa2 cells in vivo in tumor xenograft studies in immune-deficient mice without causing any weight loss or overt toxicity.|Products are for research use only. Not for human use.|